Supernus Pharmaceuticals | SUPN - 销售收入

金融业

USD

USD 1.45B

现金及等价物

USD 151.37M

USD 47.53M

USD 644.18M

USD 338.17M

USD 42.21M

USD 13.82M

USD 48.5M

674

EPS每股收益

USD -0.07

股本和储备

USD 1.06B

USD 164.04M

债务利息支出

USD 910K

USD 2.28M

USD 400.38M

USD 2.79B

USD -45.12M

USD 197.75M

USD 13.82M

普通股股本

USD 57.12M

110.38

USD -1.91M

USD 211.6M

销售和管理费用

USD 122.39M

USD 107.1M

贸易债权人

USD 107.8M

应收帐款人

USD 187.8M

	销售	更改		日
Abbott	USD 11.46B		90M	2025-12
ANI Pharmaceuticals	USD 247.06M		19.25M	2025-12
Aurora Cannabis	CAD 94.19M		3.82M	2025-12
Bristol-Myers Squibb	USD 12.5B		300M	2025-12
Canopy Growth	CAD 74.54M		7.86M	2025-12
Cara Therapeutics	USD 2.57M		1.11M	2025-03
Corcept Therapeutics	USD 202.12M		5.48M	2025-12
Eisai	JPY 219.94B		22.58B	2025-12
Eli Lilly	USD 19.3B		1.7B	2025-12
Novo Nordisk	DKK 79.14B		4.16B	2025-12
Pacira	USD 196.87M		17.35M	2025-12
Perrigo	USD 1.11B		70M	2025-12
Pfizer	USD 17.58B		880M	2025-12
Supernus Pharmaceuticals	USD 211.6M		19.5M	2025-12
United Therapeutics	USD 790.2M		9.3M	2025-12
Xeris Pharmaceuticals	USD 85.81M		11.43M	2025-12